Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our infant formula products provide superior value to consumers and customers and play an important role during the first years of life |
| And so we're taking a benefit of that and we're seeing very great momentum that continues from Q4 into Q1 in our international business, mainly fueled by pricing increase |
| So we're seeing very positive pricing actions taken |
| So I would say the health of the business has improved significantly |
| We ended 2023 with our international business firing on all cylinders, while our US OTC business is performing well as well, amid a normalizing consumer environment as store brands continue to gain market share from national brands |
| In addition, our accretive initiatives with synergies from the HRA acquisition and our Supply Chain Reinvention Program are adding value and remain on track |
| We were proud to also achieve a multidecade effort to win FDA regulatory approval for Opill, the first women's contraceptive to be available over the counter in the United States |
| And also importantly from a cash standpoint, the team did an amazing job and had contributing almost $50 million on reduction in inventories at the end of 2023 |
| And I am confident that that farm is absolutely on the right track |
| Net sales in fiscal 2023 grew nearly 5%, driven by our international and core US OTC businesses |
| This Opill launch has really improved commercially over the last six or seven months as we've built in new brand building capability, new agency partners, etcetera |
| We have very high ACV distribution plan for this, very strong retail launch plan, very strong online, very good digital program, very good communication |
| Gross margin, which has been a major focus for improvement expanded 260 basis points to 38.8% and operating margin expanded 130 basis points to 12.3% for the full year |
| Fourth quarter EPS grew 15%, leading to a full-year EPS of $2.58, an increase of 25% compared to the prior year |
| And importantly, we delivered very strong cash flow conversion of 115% for the full year |
| And then in the second half -- second quarter, we have also very strong performance |
| And earnings per share, excluding infant formula is growing mid-teens, which is, again, in line to ahead of expectations |
| Healthy Lifestyle also contributed strong growth, driven by the US smoking cessation products |
| Cough cold sales in the US grew mid-single digits, driven in part by share gains and restocking of liquid cough cold products, which were constrained in the prior year |
| Gross margin in 2024 is expected to expand to 40%, 2024 in line to ahead of expectations |
| We have initiated Project Energize, which will make us more efficient and agile, while providing a bridge to 2025, we expect our infant formula business to be augmented and strengthened for the full year and beyond |
| The margin improvement I just mentioned included benefits from our ongoing accretive initiatives |
| Excluding infant formula from both years, we expect the gross margin to continue to grow strongly in 2024, due in part to benefits from our Supply Chain Reinvention Program |
| Full-year adjusted earnings per share of $2.58 increased almost 25%, driven by business growth, including benefits from Supply Chain Reinvention Program, acquisitions, and no repeating tax benefits |
| Fiscal 2023 gross margin expanded to 160 basis points to 38.8%, driven by the factors I just mentioned, including a 30 basis points benefit from SKU prioritization actions |
| In fact, this quarter marks the sixth consecutive quarter of year-over-year gross and operating margin expansion, which was achieved through: first, strategic pricing actions; second, higher-margin acquisitions; and third, benefits from our Supply Chain Reinvention Program |
| The team has consistently delivered margin expansion since 2022 |
| It also provides value to consumers as it is price-inclusive and allow Perrigo to provide high-quality self-care products across all consumer price points and, of course, to Perrigo, as the top-line growth and margin structure are both highly accretive to our overall business |
| Perrigo is uniquely positioned to bring this model to market |
| First, we have several favorable trends, including momentum in our international and US OTC businesses, benefits from Project Energize, contributions from our Supply Chain Reinvention Program, and synergies from the HRA acquisition |
| Statement |
|---|
| So it sounds like you expect first quarter top line for infant to be the worst |
| The path we were on was costing us a lot, approximately between $80 million to $100 million OI drag over 12 months, through a combination of lost production, scrap, and higher operating costs |
| To dig a bit deeper, we expect quarter one 2024 infant formula operating income to be approximately $50 million lower than prior year, building back to flat versus the prior year in the second quarter |
| Driven primarily by an estimated negative $0.30 earnings per share impact from infant formula, Q1 earnings per share is expected to decline by nearly half compared to the prior year |
| Due to unabsorbed overhead and depressed sales volumes resulting from these resets, infant formula operating income in 2024 is now expected to be below 2023 levels, where previously we expected a recovery |
| Also, given the cash required to implement Project Energize and infant formula investments, we will pay down $400 million in bonds due at the end of the year versus our initial thoughts to pay these bonds early, which has a negative earnings per share impact of $0.05 to our initial outlook |
| Q1 2024 net sales are expected to decline a high single-digit percentage compared to the prior year due to infant formula, lower sales in the US OTC as customer inventories normalize, and the negative impact from SKU prioritization actions in CSCA |
| Organic net sales for the fourth quarter declined 0.6%, which included base business growth of 1.7%, driven by performance in Healthy Lifestyle and Digestive Health categories |
| We were also facing some regulatory hurdles in that particular business |
| So the first and the second quarter on nutrition, we expect to be below last year |
| These changes resulted in lower manufacturing output and production yields across our network |
| Company reported a GAAP net loss of $4 million or a loss of $0.03 per diluted share |
| This was evidenced by another FDA 483 in late November at Wisconsin |
| We also assume business exits with a corresponding reduction in earnings |
| These benefits were offset by infant formula, SKU prioritization actions and lower cough cold sales in Europe due to lower incidence levels |
| More importantly, we were not getting to where we needed to be from a compliance standpoint |
| So remember, we had significant impact in 2022, mainly because of the disruptions after COVID and additional logistic costs |
| Then, in late November of last year the FDA issued a Form 483 to our Wisconsin facility, which we acquired in November 2022 |
| Also not contemplated in the November initial outlook was the operating income reduction from expected portfolio refinement and exited products |
| And finished product testing alone, okay, cannot be sufficient to confirm product safety |
Please consider a small donation if you think this website provides you with relevant information